Pembrolizumab Plus Chemo Could Represent New SOC in Advanced/Recurrent Endometrial Cancer
Ramez N. Eskander, MD, discusses updated data for pembrolizumab plus chemotherapy in patients with advanced/recurrent endometrial cancer.
Ramez N. Eskander, MD, discusses updated data for pembrolizumab plus chemotherapy in patients with advanced/recurrent endometrial cancer.
Glecirasib elicited responses and demonstrated a manageable safety profile in patients with pretreated advanced NSCLC harboring KRAS G12C mutations.
R. Lor Randall, MD, FACS, discusses research examining ALDH1A1 and CD44, potential markers of osteosarcoma stem cells, and how further research may be warranted with…
Benjamin Tomlinson, MD, discusses the first-line approval of luspatercept and other ongoing research in low-risk MDS.
Oncology Times reports essential clinical news for oncologists, hematologists and other cancer care
Katherine Wang, MD, discusses the role of active surveillance for patients with renal masses and the ongoing MUSIC-KIDNEY project in Michigan.
An abstract is unavailable.
Assisting Healthcare Providers with Expanded Access Requests for Investigational Oncology Products
Addiction researcher Francesco Versace, Ph.D., studies how the brain responds to nicotine. Here, he answers some common questions about vaping and how it impacts brain…
Drs Merkow and Connell discuss the use of HAI therapy for patients with colorectal cancer.
The novel EHA/EBMT grading of ICAHT closely reflects the extent of hematological toxicity following BCMA- and CD19-directed CAR-T therapy.Severe ICAHT was